hit counter

9 New Anxiety Medications (2018): Drugs In Clinical Trials

Collected data from the Anxiety and Depression Association of America (ADAA) suggests that upwards of 40 million adults are affected by anxiety, or approximately 18% of the United States population.  Among the 40 million adults who are affected by anxiety, it is estimated that approximately: 19 million suffer from specific phobias; 15 million suffer from …

Read more

Vraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder

Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder.  In clinical trials, the drug was referenced as “RGH-188” – containing Cariprazine as the primary active ingredient.  The drug had completed Phase III clinical trials in 2012, and was pending FDA approval for …

Read more

6 New Autism Medications (2015): Drugs In Clinical Trials

Autism spectrum disorder (ASD) is a severe neurodevelopmental disorder that significantly affects behavior, cognitive function, and social skills.  Those with the disorder often engage in repetitive behaviors, suffer from low intelligence, and have severe difficulty verbalizing their thoughts.  In fact, a subset individuals with autism are incapable of any verbal communication and resort to gesturing …

Read more

3 New Narcolepsy Medications (2015) In Clinical Trials

Narcolepsy is a neurological disorder associated with the brain’s inability to regulate sleep-wake cycles (and the circadian rhythm).  As a result, individuals diagnosed with narcolepsy often experience excessive daytime sleepiness and may fall asleep unexpectedly.  Some have suggested that the excessive daytime sleepiness stemming from narcolepsy is akin to how a normal person feels if …

Read more

3 New Bipolar Medications (2015): Drugs In Clinical Trials

Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania).  For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood).  Diagnostically, there are multiple types …

Read more

14 New ADHD Medications In the Pipeline (2015)

ADHD (attention-deficit/hyperactivity disorder) is a condition characterized by inability to concentrate and often comorbid hyperactive behaviors.  It is considered the most common psychiatric disorder among children and adolescents (affecting approximately 5%) and is fairly common among adults (affecting approximately 4%).  Individuals with ADHD may face serious difficulties completing projects, studying at school, holding a steady …

Read more

20 New Antidepressants In The Pipeline (2015): Drugs In Clinical Trials

For individuals in the United States between the age of 15 and 44, major depression is the leading cause of disability.  Major depression is often a heritable condition, caused by maladaptive genes getting transferred across generations.  That said, not everyone diagnosed with major depressive disorder inherited the condition from ancestors or should be blaming their …

Read more